LivaNova (LIVN) Scheduled to Post Quarterly Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is scheduled to post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect LivaNova to post earnings of $0.47 per share for the quarter. LivaNova has set its FY 2024 guidance at 2.950-3.050 EPS and its FY24 guidance at $2.95-3.05 EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.10. The firm had revenue of $310.10 million during the quarter, compared to analyst estimates of $287.65 million. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The business’s quarterly revenue was up 12.8% compared to the same quarter last year. During the same period last year, the company posted $0.81 EPS. On average, analysts expect LivaNova to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

LivaNova Price Performance

NASDAQ LIVN opened at $55.53 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of 173.54 and a beta of 0.89. The company has a 50 day simple moving average of $54.13 and a 200-day simple moving average of $50.66. LivaNova has a 52-week low of $42.75 and a 52-week high of $59.86.

Analyst Ratings Changes

Several equities research analysts recently commented on LIVN shares. Barclays boosted their price target on LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a research note on Monday, February 26th. StockNews.com raised shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday. Needham & Company LLC restated a “buy” rating and set a $72.00 price target on shares of LivaNova in a report on Wednesday, March 20th. Mizuho reiterated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a report on Wednesday, March 27th. Finally, Robert W. Baird raised their target price on LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a report on Thursday, February 22nd. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $64.40.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.